U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C21H27NO2.ClH
Molecular Weight 361.906
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ETAFENONE HYDROCHLORIDE

SMILES

Cl.CCN(CC)CCOC1=CC=CC=C1C(=O)CCC2=CC=CC=C2

InChI

InChIKey=BYWIEEUABBZFEE-UHFFFAOYSA-N
InChI=1S/C21H27NO2.ClH/c1-3-22(4-2)16-17-24-21-13-9-8-12-19(21)20(23)15-14-18-10-6-5-7-11-18;/h5-13H,3-4,14-17H2,1-2H3;1H

HIDE SMILES / InChI

Description
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/6482088 | https://www.ncbi.nlm.nih.gov/pubmed/582134 | https://www.ncbi.nlm.nih.gov/pubmed/469443 | https://www.ncbi.nlm.nih.gov/pubmed/94412 | http://www.drugfuture.com/chemdata/etafenone.html | https://www.ncbi.nlm.nih.gov/pubmed/582134 | https://www.ncbi.nlm.nih.gov/pubmed/94412 | https://www.ncbi.nlm.nih.gov/pubmed/1037264 | https://www.ncbi.nlm.nih.gov/pubmed/1786372

Etafenone is an antiarrhythmic and coronary vasodilator drug. Etafenone exerts negative inotropic action on myocardium. It is able to block calcium channels. As a coronary vasodilator which produces a decrease in the heart rate and myocardial oxygen consumption, etafenone has been used in the therapy of ischemic heart disease.

CNS Activity

CNS Active
3913
Curator's Comment: Etafenone induces catalepsy in mice. No human data available.

Originator

DiPaco, G.|Tauro,S.C.
2
Sources: G. DiPaco, S. C. Tauro, Ann. Chim. (Rome) 48, 1215 (1958)
Curator's Comment: reference retrieved from http://www.drugfuture.com/chemdata/etafenone.html

Approval Year

Unknown
139594
Targets

Targets

Primary TargetPharmacologyConditionPotency
Binding Agent
1064
 2.43 µM [Ki]
Binding Agent
1064
 3.92 µM [Ki]
Binding Agent
1064
 0.184 µM [Ki]
Inhibitor
8297
Blocker
537
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8429
DIALICOR

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
[Pharmacological study of some properties of LG-11457. Action on ventricular extrasystoles, on spasm of smooth muscles and on the peripheral circulation].
1960 Sep 1
[Preliminary observations on the treatment of coronary insufficiency with 2'-(2-diethylaminoethoxy)-3-phenylpropiophenone hydrochloride (LG--11457)].
1960 Sep 1
[Pharmacological and toxicological studies on the effect characterization of etafenone].
1969 Oct
[Modification of the cardiostimulatory and coronary dilator effect of isopreenaline caused by etafenone].
1975 Jan
Effect of etafenone on total and regional myocardial blood flow.
1975 Sep
Effects of etafenone and antiarrhythmic drugs on Na and Ca channels of guinea pig atrial muscle.
1979 Sep-Oct
Effects of etafenone on myocardial energy metabolism as studied by an organ redoximeter and biochemical analyses.
1984 Jul
Propiverine-induced Parkinsonism: a case report and a pharmacokinetic/pharmacodynamic study in mice.
2000 May
Patents

Patents

DE1265758
2

Sample Use Guides

In Vitro Use Guide
After etafenone 1 uM, there was a significant prolongation of the time to the detectable or the maximum increase in NADH fluorescence in isolated perfused guinea pig heart
Name Type Language
ETAFENONE HYDROCHLORIDE
JAN   MART.   WHO-DD  
Common Name English
NSC-166350
Code English
Etafenone hydrochloride [WHO-DD]
Common Name English
ETAFENONE HCL
Common Name English
HEPTAPHENONE
Common Name English
ETAFENONE HYDROCHLORIDE [JAN]
Common Name English
LG-11457
Code English
2'-(2-DIETHYLAMINOETHOXY)-3-PHENYLPROPIOPHENONE HYDROCHLORIDE
Systematic Name English
ETAFENONE HYDROCHLORIDE [MART.]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C48149
Created by admin on Fri Dec 15 18:58:45 GMT 2023 , Edited by admin on Fri Dec 15 18:58:45 GMT 2023
Code System Code Type Description
SMS_ID
100000087296
Created by admin on Fri Dec 15 18:58:45 GMT 2023 , Edited by admin on Fri Dec 15 18:58:45 GMT 2023
PRIMARY
CAS
2192-21-4
Created by admin on Fri Dec 15 18:58:45 GMT 2023 , Edited by admin on Fri Dec 15 18:58:45 GMT 2023
PRIMARY
DRUG BANK
DBSALT002643
Created by admin on Fri Dec 15 18:58:45 GMT 2023 , Edited by admin on Fri Dec 15 18:58:45 GMT 2023
PRIMARY
EVMPD
SUB01980MIG
Created by admin on Fri Dec 15 18:58:45 GMT 2023 , Edited by admin on Fri Dec 15 18:58:45 GMT 2023
PRIMARY
EPA CompTox
DTXSID60176336
Created by admin on Fri Dec 15 18:58:45 GMT 2023 , Edited by admin on Fri Dec 15 18:58:45 GMT 2023
PRIMARY
FDA UNII
NTS160XKGC
Created by admin on Fri Dec 15 18:58:45 GMT 2023 , Edited by admin on Fri Dec 15 18:58:45 GMT 2023
PRIMARY
NCI_THESAURUS
C95811
Created by admin on Fri Dec 15 18:58:45 GMT 2023 , Edited by admin on Fri Dec 15 18:58:45 GMT 2023
PRIMARY
PUBCHEM
102220
Created by admin on Fri Dec 15 18:58:45 GMT 2023 , Edited by admin on Fri Dec 15 18:58:45 GMT 2023
PRIMARY
ECHA (EC/EINECS)
218-587-9
Created by admin on Fri Dec 15 18:58:45 GMT 2023 , Edited by admin on Fri Dec 15 18:58:45 GMT 2023
PRIMARY
MESH
C001162
Created by admin on Fri Dec 15 18:58:45 GMT 2023 , Edited by admin on Fri Dec 15 18:58:45 GMT 2023
PRIMARY
NSC
166350
Created by admin on Fri Dec 15 18:58:45 GMT 2023 , Edited by admin on Fri Dec 15 18:58:45 GMT 2023
PRIMARY
ChEMBL
CHEMBL1736151
Created by admin on Fri Dec 15 18:58:45 GMT 2023 , Edited by admin on Fri Dec 15 18:58:45 GMT 2023
PRIMARY
ACTIVE MOIETY
Structure of ETAFENONE
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966